Mol Cancer Ther (2023) 22 (12_Supplement): PR014.

You do not currently have access to this content.

Abstract. Previously, we reported on a series of highly potent, selective, and non-covalent CDK7 inhibitors that demonstrated antiproliferative activity against triple-negative breast cancer (TNBC) ...

Cancer Immunol Res (2022) 10 (12_Supplement): B04.

Cancer Res (2026) 86 (8_Supplement): CT184.

Cancer Res (2023) 83 (8_Supplement): LB321. Citation Format: Elizabeth Donohue Vo, Yang W. Zhang, Dave Rominger, Jillian M. Silva, Yang J. Zhang, Greg Lee, John ...

Cancer Immunol Res (2026) 14 (2_Supplement): A038.

Cancer Res (2024) 84 (6_Supplement): 3315. Conclusion: TSN1611 is a selective KRAS G12D inhibitor. It exhibited excellent selectivity and activity both in vitro and in vivo; it demonstrated favorable ...

Annual Meeting 2025 AACR Journals Simultaneous Publications | American Association for Cancer Research AACR Annual Meeting 2025: AACR Journals’ Concurrent Publications These journal articles published ...

Cancer Res (2025) 85 (8_Supplement_1): 841. Measurement of plasma and tumor concentrations were completed using standard extraction techniques with quantitation by LC-MS/MS methods. Target modulation ...

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...